--- title: "Arbutus Biopharma (ABUS) news: merger, lawsuit and settlement" url: "https://aibio.space/companies/arbutus-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABUS merger, lawsuit, settlement and buyback news: Arbutus Biopharma starts tender offer for up to US$230 million of its shares." --- ABUS Arbutus Biopharma Corporation NASDAQ · United States # Arbutus Biopharma (ABUS) news ABUS merger, lawsuit, settlement and buyback news Financings · 2026-08-24 ## [Arbutus Biopharma starts tender offer for up to US$230 million of its shares](https://aibio.space/news/arbutus-biopharma-starts-tender-offer-up-us-230-million-shares/) Arbutus filed a Schedule TO on August 24, 2026 to start an issuer tender offer for up to US$230 million of its common shares, paid in cash. The filing points to an Offer to Purchase dated the same day, and it does not state the start or expiry dates in its own text. ## Latest Arbutus Biopharma news 1. 2026-08-21 Mergers [Arbutus plans US$230 million Dutch auction tender offer for its shares](https://aibio.space/news/arbutus-plans-us-230-million-dutch-auction-tender-offer-shares/) Arbutus said on August 21, 2026 that it plans a modified Dutch auction tender offer for up to US$230 million of its common shares at US$5.00 to US$5.75 each, funded from cash on hand. The offer has not started, and the company says it needs exemptive relief in Canada and the United States first. 2. 2026-07-16 Distress [Arbutus expects to return up to approximately $230M to shareholders](https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/) Arbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026. 3. 2026-03-03 Legal [Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026](https://aibio.space/news/arbutus-genevant-settle-moderna-lnp-patent-litigation-950-0-million/) Moderna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties. 4. 2025-04-03 Legal [Arbutus says court moved Moderna patent trial to September 29, 2025](https://aibio.space/news/arbutus-says-court-moved-moderna-patent-trial-september-29-2025/) Arbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025. ## Arbutus Biopharma at a glance - **Ticker**: ABUS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $92.6 million ### Related companies - [Aktis Oncology](https://aibio.space/companies/aktis-oncology/) NASDAQ: AKTS - [Corbus Pharmaceuticals Holdings](https://aibio.space/companies/corbus-pharmaceuticals/) NASDAQ: CRBP - [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL - [Prestige Consumer Healthcare](https://aibio.space/companies/prestige-consumer-healthcare/) NYSE: PBH - [Xenetic Biosciences](https://aibio.space/companies/xenetic-biosciences/) NASDAQ: XBIO - [Harbor Diversified](https://aibio.space/companies/harbor-diversified/) OTC: HRBR - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [Oncology Pharma](https://aibio.space/companies/oncology-pharma/) OTC: ONPH ### Also on NASDAQ - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) ELOX - [Cytokinetics](https://aibio.space/companies/cytokinetics/) CYTK - [Prenetics Global](https://aibio.space/companies/prenetics-global/) PRE - [Autonomix Medical](https://aibio.space/companies/autonomix-medical/) AMIX - [ASP Isotopes](https://aibio.space/companies/asp-isotopes/) ASPI - [Foghorn Therapeutics](https://aibio.space/companies/foghorn-therapeutics/) FHTX ## What Arbutus Biopharma does Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease. It is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, for chronic hepatitis B. Arbutus stopped its discovery efforts in 2024 to focus on those two programs. It also protects its patented lipid nanoparticle (LNP) technology. Its lawsuit against Pfizer Inc. and BioNTech SE over LNP use in COVID-19 mRNA vaccines is ongoing, and a claim construction ruling in September 2025 construed disputed terms in a manner the company generally considers favorable. On March 3, 2026, Arbutus and Genevant Sciences GmbH entered a settlement agreement with Moderna, Inc. to resolve LNP patent litigation. Moderna will make an aggregate $950.0 million noncontingent lump sum payment on or before July 8, 2026, and a contingent lump sum payment of $1.3 billion depends on a favorable ruling in a limited appeal. Arbutus receives 20% of the noncontingent payment after litigation costs under its license with Genevant, and owns approximately 16% of Genevant's common equity. The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026. | Product or program | What it is | Stage | |---|---|---| | Imdusiran (AB-729) | GalNAc-conjugated RNA interference therapeutic for chronic hepatitis B | | | AB-101 | Oral PD-L1 inhibitor for chronic hepatitis B | | Summarised from the company's [10-K filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm). ## Arbutus Biopharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$14.1 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | | Research and development | [$25.2 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | [$54.0 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | | Net income (loss) | [-$33.5 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | [-$69.9 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | | Cash from operations | [-$39.6 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | [-$64.8 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | | Cash and equivalents | [$18.0 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/) | [$36.3 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | | Short-term investments | [$73.5 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | [$86.3 million](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $19.2 million, plus short-term investments of $73.5 million, $92.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Arbutus Biopharma Is Arbutus Biopharma involved in a merger or acquisition? Our latest story on this, dated Aug 24, 2026: "Arbutus Biopharma starts tender offer for up to US$230 million of its shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arbutus-biopharma-starts-tender-offer-up-us-230-million-shares/). Is Arbutus Biopharma involved in a lawsuit? Our latest story on this, dated Mar 3, 2026: "Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arbutus-genevant-settle-moderna-lnp-patent-litigation-950-0-million/). Has Arbutus Biopharma settled a lawsuit? Our latest story on this, dated Mar 3, 2026: "Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arbutus-genevant-settle-moderna-lnp-patent-litigation-950-0-million/). Does Arbutus Biopharma have a share buyback? Our latest story on this, dated Jul 16, 2026: "Arbutus expects to return up to approximately $230M to shareholders". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/). What is the ticker symbol of Arbutus Biopharma? Arbutus Biopharma Corporation trades under the ticker ABUS on NASDAQ. Where is Arbutus Biopharma listed? Arbutus Biopharma Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:I9DN; LS:A14XMD; LSX:A14XMD. What is the SEC CIK of Arbutus Biopharma? The SEC Central Index Key (CIK) for Arbutus Biopharma Corporation is 1447028. Its filings are on SEC EDGAR. How many shares does Arbutus Biopharma have outstanding? 197,847,835 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Arbutus Biopharma listed under? Our directory records Arbutus Biopharma Corporation under United States. What does Arbutus Biopharma do? Our directory classifies Arbutus Biopharma Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Arbutus Biopharma? The ISIN recorded for Arbutus Biopharma Corporation is CA03879J1003. Does aibio.space cover Arbutus Biopharma? aibio.space lists Arbutus Biopharma Corporation among 2,820 public biotech companies and publishes its news here as stories appear. Where is Arbutus Biopharma incorporated? SEC records list its state or country of incorporation as A1. What does Arbutus Biopharma develop? Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease. It is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, for chronic hepatitis B. Arbutus stopped its discovery efforts in 2024 to focus on those two programs. What is Imdusiran (AB-729) from Arbutus Biopharma? Imdusiran (AB-729): GalNAc-conjugated RNA interference therapeutic for chronic hepatitis B ## Investor discussion: Arbutus Biopharma Members talk about Arbutus Biopharma (ABUS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Arbutus Biopharma, newest first. Each line links the filing it comes from. 1. 2026-08-24 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1447028/000110465926100002/tm2622329-1_sctot.htm) 2. 2026-08-21 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/tm2623751d1_ex99-1.htm) 3. 2026-07-16 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/exh_991.htm) 4. 2025-06-25 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/exh_991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ABUS on TradingView](https://www.tradingview.com/symbols/NASDAQ-ABUS/). ## SEC filings and registration - **SEC name**: Arbutus Biopharma Corp - **CIK**: 1447028 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ABUS (Nasdaq) - **State or country of incorporation**: A1 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 701 VETERANS CIRCLE, WARMINSTER, PA, 18974 - **Phone**: 604-419-3200 - **Shares outstanding**: 197,847,835 as of 2026-08-10 (10-Q filed 2026-08-12) - **Former names**: TEKMIRA PHARMACEUTICALS CORP; TEKMIRA PHARMACEUTICALS Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1447028/000117184326006753/f8k_102126.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/tm2623751d1_8k.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/f8k_081226.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/f8k_071626.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/abus-20260526.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1447028/000144702826000021/abus-20260331.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/f8k_051226.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001447028), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Arbutus Biopharma Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ABUS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Arbutus Biopharma Corporation - **Ticker**: ABUS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: CA03879J1003 - **Other listed symbols**: GETTEX:I9DN; LS:A14XMD; LSX:A14XMD - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ABUS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/arbutus-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Arbutus Biopharma (ABUS) news: merger, lawsuit and settlement", 2026-10-31, https://aibio.space/companies/arbutus-biopharma/